At the news
? BEARISHIMPACT 7/10 424B5 filed Aug 11, 2026 at 16:59 ET
AbCellera Biologics Inc. filed a preliminary prospectus supplement for a $200 million underwritten public offering of common shares and pre-funded warrants. The offering follows positive Phase 2 data for its lead drug candidate, ABCL635, announced on August 10, 2026. The dilutive capital raise, coming on the heels of a positive catalyst, signals a need for cash to fund clinical development and will significantly dilute existing shareholders at a ~$9.32 reference price, creating a bearish near-term dynamic despite the positive clinical news.
- AbCellera is offering $200,000,000 of common shares and pre-funded warrants.
- The offering is priced at an undisclosed amount; the last reported sale price on August 10, 2026 was $9.32 per share.
- Net tangible book value as of June 30, 2026 was $811.7 million, or $2.65 per share, implying substantial dilution for new investors.
- Proceeds will fund continued R&D and clinical advancement of the internal pipeline, including lead program ABCL635.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access